BUFFALO, NY -- (MARKET WIRE) -- 05/29/08 -- Cleveland BioLabs, Inc. (NASDAQ: CBLI) announced today that it was highlighted in a "Sales Note" issued by Marc Robins, CFA and Chief Executive Officer of The Robins Group, LLC, a broker dealer focusing on small and micro-cap equities.

The five-page account summarized Robins's observations and conclusions from a recent visit to Cleveland BioLabs in Buffalo. In the note, which focuses primarily on Cleveland BioLabs's lead compound Protectan CBLB502, Robins states, "The real summary here is that there is more to CBLB502 radiation therapy than meets the eye and I believe they are close to realizing actual revenues and operating contribution on this front as well as surprising medical potential on several fronts which the stock market has wholly discounted." Robins also outlined his view of the present value summary of CBLB502 for the next two years, based on certain assumptions, which indicate potential earnings per share of $0.30 at 100,000 doses and $3.00 per share at 900,000 doses.

Interested parties should contact The Robins Group for more information about the note at 503-445-2490 or 877-276-2467. For more information on The Robins Group, please visit: http://www.therobinsgroup.biz/index.html. Robins Group analyst Ruthanne Roussel publishes research coverage on Cleveland BioLabs.

About Cleveland BioLabs, Inc.

Cleveland BioLabs, Inc. is a drug discovery and development company leveraging its proprietary discoveries about programmed cell death to treat cancer and protect normal tissues from exposure to radiation and other stresses. The Company has strategic partnerships with the Cleveland Clinic, Roswell Park Cancer Institute, ChemBridge Corporation and the Armed Forces Radiobiology Research Institute. To learn more about Cleveland BioLabs, Inc., please visit the company's website at http://www.cbiolabs.com.

This press release does not suggest or imply an endorsement by the Company of any recommendation or reference included in any publication by unrelated parties.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Some of the factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's periodic filings with the Securities and Exchange Commission.

Rachel Levine
Director Corporate Development & Communications
Cleveland BioLabs, Inc.
T: (646) 284-9439
E: rlevine@cbiolabs.com